22 Mar Odylia co-founder Mass Eye performs first post-approval injection of Luxturna®
Posted at 14:22h
in Press Releases
Massachusetts Eye and Ear says it has performed the first post-approval injection of the Luxturna®, which treats a form of blindness caused by RPE65 deficiency, otherwise known as RP20. The hospital announced on Tuesday that Jason Comander, the associate director of its inherited retinal disorders service, had performed the procedure on a 13-year-old boy